{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:16:05Z","timestamp":1787026565674,"version":"build-2736575974"},"reference-count":79,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T00:00:00Z","timestamp":1637193600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005150","name":"Chinese Academy of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005150","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Tumor necrosis factor (TNF) family members participate in the body\u2019s antitumor immunity response and influence tumor prognosis and treatment response. However, little is known about the roles of TNF family members in small cell lung cancer (SCLC). Therefore, we conducted the first comprehensive investigation of TNF family members in patients with SCLC, with the goal of using them to predict prognosis and chemotherapy benefit. Abnormal genetic alterations and expression of TNF family members were found to be widespread in SCLC patients. Using LASSO Cox regression analysis, we constructed a TNF family-based signature that separated SCLC patients in the training set (n=77) into high- and low-risk groups with distinct survival and chemotherapy benefit, and the signature was well-validated in the validation set (n=137) by RT-qPCR. Importantly, the signature exhibited superior predictive performance and was identified as a novel independent prognostic factor. Additionally, different immune phenotypes were found between the low-risk and high-risk groups, and high-risk patients had higher CMTM6 expression, suggesting that these patients could benefit from therapeutic methods targeting CMTM6. We constructed the first clinically applicable TNF family-based signature for predicting prognosis and chemotherapy benefit for patients with SCLC. The findings reported here provide a new method for predicting the prognosis of SCLC patients and optimizing clinical management.<\/jats:p>","DOI":"10.3389\/fimmu.2021.745769","type":"journal-article","created":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T04:04:31Z","timestamp":1637208271000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Tumor Necrosis Factor Family Member Profile Predicts Prognosis and Adjuvant Chemotherapy Benefit for Patients With Small-Cell Lung Cancer"],"prefix":"10.3389","volume":"12","author":[{"given":"Zhihui","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaoqi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuejun","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guochao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingpeng","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lide","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoyang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,11,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60165-7","article-title":"Small-Cell Lung Cancer","volume":"378","author":"van Meerbeeck","year":"2011","journal-title":"LANCET"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29098","article-title":"Small Cell Lung Cancer: Where do We Go From Here","volume":"121","author":"Byers","year":"2015","journal-title":"CANCER-AM Cancer Soc"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2017.87","article-title":"Small-Cell Lung Cancer: What We Know, What We Need to Know and the Path Forward","volume":"17","author":"Gazdar","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e318286cf88","article-title":"Rationale for Chemotherapy, Immunotherapy, and Checkpoint Blockade in SCLC: Beyond Traditional Treatment Approaches","volume":"8","author":"Spigel","year":"2013","journal-title":"J Thorac Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2009-0298","article-title":"Limited-Stage Small Cell Lung Cancer: Current Chemoradiotherapy Treatment Paradigms","volume":"15","author":"Stinchcombe","year":"2010","journal-title":"ONCOLOGIST"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.2015.009225","article-title":"Small-Cell Lung Cancer: New Directions for Systemic Therapy","volume":"12","author":"Ramalingam","year":"2016","journal-title":"J Oncol Pract"},{"key":"B7","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1186\/s40425-019-0690-1","article-title":"Immunotherapy in Small-Cell Lung Cancer: From Molecular Promises to Clinical Challenges","volume":"7","author":"Pavan","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab Versus Docetaxel for Previously Treated, PD-L1-Positive, Advanced Non-Small-Cell Lung Cancer (KEYNOTE-010): A Randomised Controlled Trial","volume":"387","author":"Herbst","year":"2016","journal-title":"LANCET"},{"key":"B9","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s40425-019-0572-6","article-title":"Use of Targeted Next Generation Sequencing to Characterize Tumor Mutational Burden and Efficacy of Immune Checkpoint Inhibition in Small Cell Lung Cancer","volume":"7","author":"Ricciuti","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3670","article-title":"Tumour Antigens Recognized by T Lymphocytes: At the Core of Cancer Immunotherapy","volume":"14","author":"Coulie","year":"2014","journal-title":"Nat Rev Cancer"},{"key":"B11","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s13045-019-0753-2","article-title":"Potential Immune Escape Mechanisms Underlying the Distinct Clinical Outcome of Immune Checkpoint Blockades in Small Cell Lung Cancer","volume":"12","author":"Tian","year":"2019","journal-title":"J Hematol Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809064","article-title":"First-Line Atezolizumab Plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32222-6","article-title":"Durvalumab Plus Platinum-Etoposide Versus Platinum-Etoposide in First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer (CASPIAN): A Randomised, Controlled, Open-Label, Phase 3 Trial","volume":"394","author":"Paz-Ares","year":"2019","journal-title":"LANCET"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00793","article-title":"Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study","volume":"38","author":"Rudin","year":"2020","journal-title":"J Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.05.002","article-title":"Phase II Study of Maintenance Pembrolizumab in Patients With Extensive-Stage Small Cell Lung Cancer (SCLC)","volume":"13","author":"Gadgeel","year":"2018","journal-title":"J Thorac Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.6601","article-title":"Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer","volume":"34","author":"Reck","year":"2016","journal-title":"J Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the Tumor Immune Microenvironment (TIME) for Effective Therapy","volume":"24","author":"Binnewies","year":"2018","journal-title":"Nat Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"eaaz0463","DOI":"10.1126\/scitranslmed.aaz0463","article-title":"Immune Landscapes Predict Chemotherapy Resistance and Immunotherapy Response in Acute Myeloid Leukemia","volume":"12","author":"Vadakekolathu","year":"2020","journal-title":"Sci Transl Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1038\/s41392-020-00221-8","article-title":"An Individualized Immune Signature of Pretreatment Biopsies Predicts Pathological Complete Response to Neoadjuvant Chemoradiotherapy and Outcomes in Patients With Esophageal Squamous Cell Carcinoma","volume":"5","author":"Zhang","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"B20","doi-asserted-by":"publisher","first-page":"a028431","DOI":"10.1101\/cshperspect.a028431","article-title":"The Tumor Necrosis Factor Family: Family Conventions and Private Idiosyncrasies","volume":"10","author":"Wallach","year":"2018","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/nri2526","article-title":"The Role of TNF Superfamily Members in T-Cell Function and Diseases","volume":"9","author":"Croft","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2007.06.001","article-title":"TNF Family Ligands Define Niches for T Cell Memory","volume":"28","author":"Sabbagh","year":"2007","journal-title":"Trends Immunol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"8691","DOI":"10.3390\/ijms22168691","article-title":"Tnf\u03b1 and Immune Checkpoint Inhibition: Friend or Foe for Lung Cancer","volume":"22","author":"Benoot","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B24","doi-asserted-by":"publisher","first-page":"564","DOI":"10.3390\/cancers13030564","article-title":"Harnessing Tumor Necrosis Factor Alpha to Achieve Effective Cancer Immunotherapy","volume":"13","author":"Mercogliano","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01818","article-title":"The TNF Paradox in Cancer Progression and Immunotherapy","volume":"10","author":"Montfort","year":"2019","journal-title":"Front Immunol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nature14664","article-title":"Comprehensive Genomic Profiles of Small Cell Lung Cancer","volume":"524","author":"George","year":"2015","journal-title":"NATURE"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0506580102","article-title":"Gene Set Enrichment Analysis: A Knowledge-Based Approach for Interpreting Genome-Wide Expression Profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-14-7","article-title":"GSVA: Gene Set Variation Analysis for Microarray and RNA-Seq Data","volume":"14","author":"H\u00e4nzelmann","year":"2013","journal-title":"BMC Bioinf"},{"key":"B29","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1038\/ncomms3612","article-title":"Inferring Tumour Purity and Stromal and Immune Cell Admixture From Expression Data","volume":"4","author":"Yoshihara","year":"2013","journal-title":"Nat Commun"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2628","article-title":"Tumour Necrosis Factor and Cancer","volume":"9","author":"Balkwill","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"B31","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1146\/annurev.immunol.23.021704.115839","article-title":"TNF\/TNFR Family Members in Costimulation of T Cell Responses","volume":"23","author":"Watts","year":"2005","journal-title":"Annu Rev Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellbi.2009.02.001","article-title":"TNF Superfamily: Costimulation and Clinical Applications","volume":"33","author":"Vinay","year":"2009","journal-title":"Cell Biol Int"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1172\/JCI32567","article-title":"TNF-Alpha Is Critical for Antitumor But Not Antiviral T Cell Immunity in Mice","volume":"117","author":"Calzascia","year":"2007","journal-title":"J Clin Invest"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/nature02924","article-title":"NF-Kappab Functions as a Tumour Promoter in Inflammation-Associated Cancer","volume":"431","author":"Pikarsky","year":"2004","journal-title":"NATURE"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1172\/JCI32453","article-title":"Blocking TNF-Alpha in Mice Reduces Colorectal Carcinogenesis Associated With Chronic Colitis","volume":"118","author":"Popivanova","year":"2008","journal-title":"J Clin Invest"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/emboj.2008.105","article-title":"Activated Macrophages Promote Wnt Signalling Through Tumour Necrosis Factor-Alpha in Gastric Tumour Cells","volume":"27","author":"Oguma","year":"2008","journal-title":"EMBO J"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1084\/jem.177.5.1391","article-title":"Enhancement of Experimental Metastasis by Tumor Necrosis Factor","volume":"177","author":"Orosz","year":"1993","journal-title":"J Exp Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/nature07623","article-title":"Carcinoma-Produced Factors Activate Myeloid Cells Through TLR2 to Stimulate Metastasis","volume":"457","author":"Kim","year":"2009","journal-title":"NATURE"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-5704","article-title":"Anti-Tumor Necrosis Factor Therapy Inhibits Pancreatic Tumor Growth and Metastasis","volume":"68","author":"Egberts","year":"2008","journal-title":"Cancer Res"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1987.294","article-title":"Tumour Necrosis Factor in Man: Clinical and Biological Observations","volume":"56","author":"Selby","year":"1987","journal-title":"Br J Cancer"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.11.2205","article-title":"Phase I Clinical Trial of Recombinant Human Tumor Necrosis Factor in Children With Refractory Solid Tumors: A Pediatric Oncology Group Study","volume":"11","author":"Furman","year":"1993","journal-title":"J Clin Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.19.1.163","article-title":"Anti-TNF Alpha Therapy of Rheumatoid Arthritis: What Have We Learned","volume":"19","author":"Feldmann","year":"2001","journal-title":"Annu Rev Immunol"},{"key":"B43","article-title":"Phase I Study of Recombinant Tumor Necrosis Factor in Cancer Patients","volume":"47","author":"Blick","year":"1987","journal-title":"Cancer Res"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3930","article-title":"Clinical Targeting of the TNF and TNFR Superfamilies","volume":"12","author":"Croft","year":"2013","journal-title":"Nat Rev Drug Discovery"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/384372a0","article-title":"A Death-Domain-Containing Receptor That Mediates Apoptosis","volume":"384","author":"Kitson","year":"1996","journal-title":"NATURE"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201141477","article-title":"Triggering of TNFRSF25 Promotes CD8\u207a T-Cell Responses and Anti-Tumor Immunity","volume":"41","author":"Slebioda","year":"2011","journal-title":"Eur J Immunol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/nri1184","article-title":"Signalling Pathways of the TNF Superfamily: A Double-Edged Sword","volume":"3","author":"Aggarwal","year":"2003","journal-title":"Nat Rev Immunol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-11-447","article-title":"TNFRSF1B +676 T>G Polymorphism Predicts Survival of Non-Small Cell Lung Cancer Patients Treated With Chemoradiotherapy","volume":"11","author":"Guan","year":"2011","journal-title":"BMC Cancer"},{"key":"B49","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.cdtm.2015.02.010","article-title":"Soluble CD40 in Plasma and Malignant Pleural Effusion With Non-Small Cell Lung Cancer: A Potential Marker of Prognosis","volume":"1","author":"Mu","year":"2015","journal-title":"Chronic Dis Transl Med"},{"key":"B50","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41419-019-1343-5","article-title":"Generation and Characterization of Novel Anti-DR4 and Anti-DR5 Antibodies Developed by Genetic Immunization","volume":"10","author":"Dubuisson","year":"2019","journal-title":"Cell Death Dis"},{"key":"B51","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3390\/antib6040016","article-title":"Antibodies and Derivatives Targeting DR4 and DR5 for Cancer Therapy","volume":"6","author":"Dubuisson","year":"2017","journal-title":"Antibodies (Basel)"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00922","article-title":"TNFSF14: Lighting the Way for Effective Cancer Immunotherapy","volume":"11","author":"Skeate","year":"2020","journal-title":"Front Immunol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02585","article-title":"The Tumor Necrosis Factor Superfamily Members Tnfsf14 (Light), Lymphotoxin \u03b2 and Lymphotoxin \u03b2 Receptor Interact to Regulate Intestinal Inflammation","volume":"9","author":"Giles","year":"2018","journal-title":"Front Immunol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00045.2017","article-title":"The TNF Family of Ligands and Receptors: Communication Modules in the Immune System and Beyond","volume":"99","author":"Dostert","year":"2019","journal-title":"Physiol Rev"},{"key":"B55","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1128\/CMR.00046-17","article-title":"The Role of BAFF System Molecules in Host Response to Pathogens","volume":"30","author":"Sakai","year":"2017","journal-title":"Clin Microbiol Rev"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.614781","article-title":"Plasma TNFSF13B and TNFSF14 Function as Inflammatory Indicators of Severe Adenovirus Pneumonia in Pediatric Patients","volume":"11","author":"Fan","year":"2020","journal-title":"Front Immunol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1204985","article-title":"Tumor Necrosis Factor-Alpha Induces the Expression of DR6, a Member of the TNF Receptor Family, Through Activation of NF-Kappab","volume":"20","author":"Kasof","year":"2001","journal-title":"ONCOGENE"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/s0014-5793(98)00791-1","article-title":"Identification and Functional Characterization of DR6, a Novel Death Domain-Containing TNF Receptor","volume":"431","author":"Pan","year":"1998","journal-title":"FEBS Lett"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1007\/978-0-387-89520-8_13","article-title":"Tumor Necrosis Factor Receptor Superfamily Member 21: TNFR-Related Death Receptor-6, DR6","volume":"647","author":"Benschop","year":"2009","journal-title":"Adv Exp Med Biol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v97.9.2702","article-title":"RELT, a New Member of the Tumor Necrosis Factor Receptor Superfamily, Is Selectively Expressed in Hematopoietic Tissues and Activates Transcription Factor NF-Kappab","volume":"97","author":"Sica","year":"2001","journal-title":"BLOOD"},{"key":"B61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cellimm.2009.10.013","article-title":"RELT Induces Cellular Death in HEK 293 Epithelial Cells","volume":"261","author":"Cusick","year":"2010","journal-title":"Cell Immunol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201847633","article-title":"RELT Negatively Regulates the Early Phase of the T-Cell Response in Mice","volume":"48","author":"Choi","year":"2018","journal-title":"Eur J Immunol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"3345","DOI":"10.1038\/s41467-019-11280-z","article-title":"Regulation of Antitumour CD8 T-Cell Immunity and Checkpoint Blockade Immunotherapy by Neuropilin-1","volume":"10","author":"Leclerc","year":"2019","journal-title":"Nat Commun"},{"key":"B64","doi-asserted-by":"publisher","first-page":"R15","DOI":"10.1186\/bcr2234","article-title":"T-Cell Metagene Predicts a Favorable Prognosis in Estrogen Receptor-Negative and HER2-Positive Breast Cancers","volume":"11","author":"Rody","year":"2009","journal-title":"Breast Cancer Res"},{"key":"B65","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1186\/s12967-019-02160-7","article-title":"The Prognostic Role of Circulating CD8(+) T Cell Proliferation in Patients With Untreated Extensive Stage Small Cell Lung Cancer","volume":"17","author":"An","year":"2019","journal-title":"J Transl Med"},{"key":"B66","doi-asserted-by":"publisher","first-page":"e001294","DOI":"10.1136\/jitc-2020-001294","article-title":"Differential Gene Expression of Tumor-Infiltrating CD8(+) T Cells in Advanced Versus Early-Stage Colorectal Cancer and Identification of a Gene Signature of Poor Prognosis","volume":"8","author":"Saleh","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B67","article-title":"CD4+ and CD8+ T Cells Cooperate to Improve Prognosis of Patients With Esophageal Squamous Cell Carcinoma","volume":"63","author":"Cho","year":"2003","journal-title":"Cancer Res"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.4325","article-title":"Prognostic and Predictive Gene Signature for Adjuvant Chemotherapy in Resected Non-Small-Cell Lung Cancer","volume":"28","author":"Zhu","year":"2010","journal-title":"J Clin Oncol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-19-0311","article-title":"Tumor Immune Microenvironment and Chemosensitivity Signature for Predicting Response to Chemotherapy in Gastric Cancer","volume":"7","author":"Jiang","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20050915","article-title":"Caspase-Dependent Immunogenicity of Doxorubicin-Induced Tumor Cell Death","volume":"202","author":"Casares","year":"2005","journal-title":"J Exp Med"},{"key":"B71","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.tcb.2020.06.003","article-title":"The Roles of CD8(+) T Cell Subsets in Antitumor Immunity","volume":"30","author":"St","year":"2020","journal-title":"Trends Cell Biol"},{"key":"B72","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.ccell.2015.10.012","article-title":"Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents","volume":"28","author":"Galluzzi","year":"2015","journal-title":"Cancer Cell"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2958","article-title":"Small Cell Lung Cancer: Will Recent Progress Lead to Improved Outcomes","volume":"21","author":"Pietanza","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B74","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s12943-019-1091-2","article-title":"Novel Immune Checkpoint Targets: Moving Beyond PD-1 and CTLA-4","volume":"18","author":"Qin","year":"2019","journal-title":"Mol Cancer"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-19-0394","article-title":"Targeting CMTM6 Suppresses Stem Cell-Like Properties and Enhances Antitumor Immunity in Head and Neck Squamous Cell Carcinoma","volume":"8","author":"Chen","year":"2020","journal-title":"Cancer Immunol Res"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1038\/nature23643","article-title":"CMTM6 Maintains the Expression of PD-L1 and Regulates Anti-Tumour Immunity","volume":"549","author":"Burr","year":"2017","journal-title":"NATURE"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.1549","article-title":"Comparison of Biomarker Modalities for Predicting Response to PD-1\/PD-L1 Checkpoint Blockade: A Systematic Review and Meta-Analysis","volume":"5","author":"Lu","year":"2019","journal-title":"JAMA Oncol"},{"key":"B78","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1038\/s41591-018-0057-z","article-title":"A Transcriptionally and Functionally Distinct PD-1(+) CD8(+) T Cell Pool With Predictive Potential in non-Small-Cell Lung Cancer Treated With PD-1 Blockade","volume":"24","author":"Thommen","year":"2018","journal-title":"Nat Med"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1038\/nature23669","article-title":"Identification of CMTM6 and CMTM4 as PD-L1 Protein Regulators","volume":"549","author":"Mezzadra","year":"2017","journal-title":"NATURE"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.745769\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T04:04:35Z","timestamp":1637208275000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.745769\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,18]]},"references-count":79,"alternative-id":["10.3389\/fimmu.2021.745769"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.745769","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,18]]},"article-number":"745769"}}